[go: up one dir, main page]

DE60324784D1 - Behandlung zur reduzierung der zunahme des körpergewichts - Google Patents

Behandlung zur reduzierung der zunahme des körpergewichts

Info

Publication number
DE60324784D1
DE60324784D1 DE60324784T DE60324784T DE60324784D1 DE 60324784 D1 DE60324784 D1 DE 60324784D1 DE 60324784 T DE60324784 T DE 60324784T DE 60324784 T DE60324784 T DE 60324784T DE 60324784 D1 DE60324784 D1 DE 60324784D1
Authority
DE
Germany
Prior art keywords
treatment
body weight
reduce increase
colipase
impedes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60324784T
Other languages
English (en)
Inventor
Douglas C Stafford
John A Kink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Application granted granted Critical
Publication of DE60324784D1 publication Critical patent/DE60324784D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Polishing Bodies And Polishing Tools (AREA)
  • Disintegrating Or Milling (AREA)
  • Glass Compositions (AREA)
DE60324784T 2002-04-26 2003-04-24 Behandlung zur reduzierung der zunahme des körpergewichts Expired - Fee Related DE60324784D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37616602P 2002-04-26 2002-04-26
US10/421,393 US20040018197A1 (en) 2002-04-26 2003-04-23 Treatment for weight loss
PCT/US2003/013035 WO2003090773A1 (en) 2002-04-26 2003-04-24 Treatment for weight loss

Publications (1)

Publication Number Publication Date
DE60324784D1 true DE60324784D1 (de) 2009-01-02

Family

ID=29273052

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324784T Expired - Fee Related DE60324784D1 (de) 2002-04-26 2003-04-24 Behandlung zur reduzierung der zunahme des körpergewichts

Country Status (7)

Country Link
US (1) US20040018197A1 (de)
EP (1) EP1503781B1 (de)
AT (1) ATE414538T1 (de)
AU (1) AU2003234245B2 (de)
CA (1) CA2484088A1 (de)
DE (1) DE60324784D1 (de)
WO (1) WO2003090773A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013455A1 (en) * 2006-07-27 2008-01-31 Lactive B.V. Means and methods for preventing elevated blood glucose levels in humans with animal antibodies produced in milk
KR101080997B1 (ko) * 2009-02-06 2011-11-09 주식회사 단바이오텍 비만과 고지혈증 예방 및 치료를 위한 특이 난황항체를 포함하는 조성물
CN102869382A (zh) * 2010-06-10 2013-01-09 (株)Ad生物技 通过抑制肠内胆固醇吸收而抑制高脂血症和肥胖症的组合物
US10645990B2 (en) * 2013-08-19 2020-05-12 Nike, Inc. Article of footwear with adjustable sole
US10681957B2 (en) * 2015-09-17 2020-06-16 Daniel Thomas Duarte Suspension bridging shoe
WO2017079299A1 (en) * 2015-11-03 2017-05-11 Mayo Foundation For Medical Education And Research Using colipase inhibitors to treat pancreatitis
CN111343999B (zh) 2017-07-12 2022-03-01 梅约医学教育与研究基金会 减少脂毒性损伤的化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
AU2678997A (en) * 1996-04-19 1997-11-12 Lexigen Pharmaceuticals Corp. Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response
FR2758143B1 (fr) * 1997-01-07 1999-02-19 Laphal Laboratoire De Pharmaco Inhibiteurs specifiques de la lipase pancreatique et leurs applications
US7344713B1 (en) * 1997-07-07 2008-03-18 Pimentel Julio L Decreased fat absorption with an anti-lipase antibody
US20030037350A1 (en) * 1999-09-29 2003-02-20 Millennium Pharmaceuticals, Inc. Novel nucleic acid sequences encoding a human ubiquitin protease, lipase, dynamin, short chain dehydrogenase, and ADAM-TS metalloprotease and uses therefor
CN1301849A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——共脂肪酶12和编码这种多肽的多核苷酸
ATE428733T1 (de) * 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
CN1343711A (zh) * 2000-09-19 2002-04-10 上海博德基因开发有限公司 一种新的多肽——人共脂肪酶蛋白9.02和编码这种多肽的多核苷酸

Also Published As

Publication number Publication date
EP1503781A4 (de) 2006-02-22
US20040018197A1 (en) 2004-01-29
EP1503781B1 (de) 2008-11-19
AU2003234245A1 (en) 2003-11-10
WO2003090773A1 (en) 2003-11-06
ATE414538T1 (de) 2008-12-15
AU2003234245B2 (en) 2006-08-03
CA2484088A1 (en) 2003-11-06
EP1503781A1 (de) 2005-02-09

Similar Documents

Publication Publication Date Title
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
ATE494904T1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
MX2007003013A (es) Amidas biciclicas como inhibidores de cinasa.
DE602007004615D1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
ATE453642T1 (de) Substituierte phenylaminopyrimidine
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
ATE247507T1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
TW200608966A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
EA200700909A1 (ru) Азаиндолкарбоксамиды
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE420099T1 (de) Medikament zur wachstumsinhibierung von tumoren
ATE447948T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
DE60324784D1 (de) Behandlung zur reduzierung der zunahme des körpergewichts
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
FR2842422B1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee